Primary Job Title Chief Executive Officer Primary Organization ATXA Therapeutics
Location Blackrock, Dublin, Ireland Regions European Union (EU), Europe, Middle East, and Africa (EMEA) Gender Male
LinkedIn View on LinkedIn
Ivan Coulter joined the company as CEO in October 2018. An experienced bio-entrepreneur, prior to joining ATXA Ivan was the founder and CEO/CSO of Sigmoid Pharma Limited (now Sublimity Therapeutics). Under his leadership Sigmoid developed an innovative oral drug delivery technology, SmPill®, and progressed the clinical development of a
SmPill®-enabled product through Phase II studies in moderate-severe ulcerative colitis.
During his time as CEO, Sigmoid brought in over €100M of partnership and financing into the company, including Series B financing in May 2018 and a European licensing deal with Dr Falk in 2017.
Ivan received a B.Sc. (Honours) degree and a PhD in Pharmacology from University College Dublin, and an MBA from Cornell University, USA. Ivan obtained a Certified Diploma in Accounting and Finance (C.Dip.A.F.) from the Association of Chartered Certified Accountants. Ivan is a lead inventor or co-inventor of over 20 patent applications. Ivan has been involved in several successful licensing and multi-disciplinary development collaborations with academic and industry partners and is the recipient of multiple national and international awards and grants.
